Tremelimumab in Melanoma
|Drug class||Target||Agent||Diseases||Line of Therapy||Status||Source|
|CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody||CTLA-4||tremelimumab||melanoma||metastatic||Trials complete with results||Ribas et al. 2013|
The CTLA-4 inhibitor tremelimumab has previously been investigated in patients with melanoma. The only phase III clinical trial of tremelimumab to date was published in 2013, and it failed to show a statistically significant improvement in overall survival when patients with previously untreated metastatic melanoma were treated with tremelimumab compared to standard chemotherapy alone (NCT00257205; Ribas et al. 2013).
|Reference||Study Type / Phase||Line of Treatment||Treatment Agent||Mutation Status||# Patients in Study||Response Rate||PFS (months)||OS (months)|
|Ribas et al. 2013||Phase III||1st||tremelimumab||328||10.7%||20.3 (6-month PFS)||12.6|
|dacarbazine or temozolamide||327||9.8%||18.1 (6-month PFS)||10.7|
Suggested Citation: Iams, W.T., D. Johnson, C. Lovly. 2015. Immunotherapy in Cancer. My Cancer Genome http://www.padiracinnovation.org/content/molecular-medicine/c49085-melanoma/ (Updated February 10).
Last Updated: June 24, 2015